/C O R R E C T I O N -- Soaak Technologies/

Soaak Technologies launched Find My Frequency, an AI-powered platform that uses wearable biometrics and user input to generate personalized sound-frequency sessions and track subsequent biometric responses. The product is available on iOS and Android and works with Apple Watch, Garmin, Google/Fitbit, ŌURA and WHOOP, though a wearable is not required. Soaak cites a study covering 18,000 nights across 550 subjects and says 90.3% of participants in ŌURA and Garmin pilots reported support for sleep quality and stress management; these are company-reported claims.

Analysis

The investable question is not whether this launch validates sound-based wellness; it is whether a third-party intervention layer can capture recurring engagement without owning the wearable, customer relationship, or distribution. If FMF improves retention or paid conversion, the benefit to Apple, Alphabet, Garmin and Oura is indirect: more perceived utility can support device replacement and ecosystem stickiness, but the release provides no evidence of revenue sharing or material device demand. Conversely, an independent app that becomes the user’s action interface could weaken platform control over wellness engagement—though access to biometrics and distribution remains dependent on the device ecosystems.

Treat efficacy and traction claims as unverified company assertions. The cited satisfaction and pilot figures do not establish controlled, durable biometric improvement or willingness to pay; post-session readings are vulnerable to placebo effects, regression to the mean and noisy wearable measurements. Privacy permissions, API access and health-claim scrutiny are additional scaling constraints. The product is explicitly not a medical treatment, which limits the clinical-value argument.

Near term, this is unlikely to alter earnings for the mapped companies; avoid extrapolating a product announcement into an AAPL, GOOG, GRMN or OURA trade. Over 1–3 months, watch app-store rankings, trial-to-paid conversion, retention, independent controlled-study results, and any disclosed platform partnership. Over 6–18 months, the larger risk is platform bundling of comparable coaching features, which could compress standalone wellness-app economics. The thesis improves with verified repeat use and measurable incremental outcomes; it weakens if engagement fades after trial, wearable integrations are restricted, or independent studies fail to reproduce the claimed benefit.

Key Decisions for Investors

• No position in AAPL, GOOG, GRMN or OURA on this announcement alone: the likely near-term earnings sensitivity is immaterial and no commercial economics with Soaak are disclosed.
• Set a 1–3 month diligence alert for independent efficacy data, paid conversion and cohort retention; do not treat usage minutes, satisfaction scores or pilot feedback as substitutes for those metrics.
• Monitor platform bundling and API access as the key competitive catalysts. Reassess the standalone-app risk if a major wearable platform launches comparable personalized intervention features or restricts third-party biometric access.
• Falsification/watch items: weak post-trial retention, no reproducible improvement versus a control group, or evidence that integrations do not support reliable remeasurement would undermine the adoption thesis; verified recurring subscriptions and durable independent outcomes would strengthen it.